Therapeutic Brief
- Australian Government Department of Health. Australian National Diabetes Strategy 2021-2030. Accessed September 2024. https://www.health.gov.au/resources/publications/australian-national-diabetes-strategy-2021-2030?language=en
- Marson A, Raffoul N, Osman R, Deed G. Management of patients with type 2 diabetes and cardiovascular disease in primary care. Australian Journal of General Practice. 2021;50(4):238-245.
- Nelson AJ, O’Brien EC, Kaltenbach LA, et al. Use of lipid-, blood pressure–, and glucose-lowering pharmacotherapy in patients with type 2 diabetes and atherosclerotic cardiovascular disease. JAMA Network Open. 2022;5(2):e2148030-e2148030.
- The Royal Australian College of General Practitioners (RACGP). Management of type 2 diabetes: A handbook for general practice. Accessed November 2024. https://www.racgp.org.au/clinical-resources/clinical-guidelines/key-racgp-guidelines/view-all-racgp-guidelines/management-of-type-2-diabetes/introduction
- Diabetes Australia. Position statement type 2 diabetes remission. Accessed July 2022. https://www.diabetesaustralia.com.au/wp-content/uploads/2021_Diabetes-Australia-Position-Statement_Type-2-diabetes-remission_2.pdf
- Stranks SN, Wittert GA. Is remission of type 2 diabetes mellitus real? Medical Journal of Australia. 2023;219(10):448-450.
- Giugliano D, Longo M, Scappaticcio L, Caruso P, Esposito K. Sodium–glucose transporter-2 inhibitors for prevention and treatment of cardiorenal complications of type 2 diabetes. Cardiovascular Diabetology. 2021;20:1-10.
- Seidu S, Cos X, Brunton S, et al. 2022 update to the position statement by Primary Care Diabetes Europe: a disease state approach to the pharmacological management of type 2 diabetes in primary care. Primary Care Diabetes. 2022;16(2):223-244.
- Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. The Lancet. 2021;398(10296):262-276.
- Ng E, Shaw JE, Wood A, Maple-Brown LJ, Hare MJL. Glucagon-like peptide-1 receptor agonist (GLP1-RA) therapy in type 2 diabetes. Australian Journal of General Practice. 2022;51(7):513-518.
- Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes care. 2018;41(12):2669.
- Abdelmasih R, Abdelmaseih R, Thakker R, et al. Update on the Cardiovascular benefits of sodium-glucose co-transporter-2 inhibitors: mechanism of action, available agents and comprehensive review of literature. Cardiology Research. 2021;12(4):210.
- Australian Medicines Handbook (AMH). Sodium-glucose co-transporter 2 inhibitors Accessed October 2024.
- Lipscombe L, Butalia S, Dasgupta K, et al. Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. Canadian Journal of Diabetes. 2020;44(7):575-591.
- Shaefer Jr CF, Kushner P, Aguilar R. User’s guide to mechanism of action and clinical use of GLP-1 receptor agonists. Postgraduate Medicine. 2015;127(8):818-826.
- Department of Health and Aged Care. PBS restriction changes to type 2 diabetes mellitus (T2DM) medicines. Accessed September 2024. https://www.pbs.gov.au/info/reviews/pbs-restriction-changes-to-type-2-diabetes-mellitus-t2dm-medicines
- Australian Medicines Handbook (AMH). Saxagliptin Accessed 10 October 2024.